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Antimicrobial stewardship (AMS) is a set of coordinated strategies to improve the use
of antimicrobials, to enhance patient outcomes, reduce antimicrobial resistance, and
decrease unnecessary costs. The pioneer years of AMS were restricted to high-income
countries (HIC), where overconsumption of antibiotics was associated with emergence
of multidrug-resistant (MDR) bacteria. AMS in low- and middle-income countries (LMIC)
is also necessary. However, programs effective in HIC may not perform as well in LMIC,
because (i) While decreased consumption of antibiotics may be an appropriate target
in overconsuming HIC, this may be dangerous in LMIC, where many patients die from
the lack of access to antibiotics; (ii) although AMS programs in HIC can be designed
and monitored through laboratory surveillance of resistance, surveillance programs are
not available in many LMIC; (iii) the heterogeneity of health care systems implies that
AMS programs must be carefully contextualized. Despite the need to individually tailor
AMS programs in LMIC, international collaborations remain highly valuable, through the
dissemination of high-quality documents and educational material, that may be shared,
adapted where needed, and adopted worldwide. This process, facilitated by modern
communication tools, combines many benefits, including: (i) saving time, a precious
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dimension for health care workers, by avoiding the duplication of similar works in different
settings; (ii) taking advantage of colleagues skills, and initiatives, through open access to
the work performed in other parts of the world; (iii) sharing experiences, so that we all
learn from each others’ successes and failures.
Keywords: antimicrobial stewardship, low- and middle- income countries, antibiotics, resistance, education
INTRODUCTION
According to the World Bank, low-income countries are defined
as those with a global national income (GNI) per capita, of ≤
1,025 US$ (2018 data for the fiscal year 2020), lower middle-
income countries are those with a GNI per capita between 1,026
and 3,995 US$, and upper middle-income countries are those
with a GNI per capita between 3,996 and 12,375 US$. These
countries are gathered under the category “low- and middle-
income countries” (LMIC), despite large heterogeneities between
them, not only in terms of resources, but also in terms of health
care systems, access to care, or the human development index
(1). Despite the caveats of this definition, LMIC is often used
to refer to countries where resources constraints are associated
with poor health, and a greater need to prioritize health care
interventions that will target the diseases with the highest impact
on public health, and be cost-effective (2). In the context of
infectious diseases and antimicrobial resistance (AMR), LMIC
in Sub-Saharan Africa and Asia carry the greatest burden. They
have to contend with weak regulatory infrastructure, over-the-
counter sales or counterfeit antimicrobials, and inappropriate
prescription practices coupled with significant gaps in diagnostic
testing and surveillance. This situation leads many to predict
that AMR will disproportionally impact populations living in
LMICs (3).
The term “antimicrobial stewardship” (AMS), first coined
in 1996 (4), is defined as a “set of coordinated strategies to
improve the use of antimicrobial medications with the goals
to enhance patient health outcomes, reduce antimicrobial
resistance, and decrease unnecessary costs” (5). Primarily
targeting the prescribers, AMS includes not only limiting
inappropriate use, but also optimizing antimicrobial selection,
dosing, route, and duration of therapy to maximize its efficacy
whilst limiting the unintended consequences, such as the
emergence of resistance, and adverse events. Initially, AMS
programs were mostly restricted to high-income countries
(HIC), where overconsumption of antibiotics was increasingly
associated with emergence of multidrug-resistant (MDR)
bacteria, and Clostridoides difficile infections. In the US, the
proven benefits of AMS programs have prompted the Centers
for Disease Control and Prevention (CDC) to recommend that
all hospitals have an AMS program, with defined core elements
(6). The CDC recommendation has recently been redefined
on a global scale (7). Although the global volume of antibiotic
use is 5–15 times higher outside, than inside hospitals, and has
been linked to the development of AMR in the community
(8), AMS programs for the community use of antibiotics
have paradoxically remained neglected. We therefore need to
prioritize AMS in the community setting. For example, the
work being undertaken in the UK (9) gives us some insight into
what is possible. There needs to be an integrated one-system
whole-health-economy approach to AMS, as recently advocated
(10). This whole system approach is likely to be more effective
and sustainable, compared to the fragmented or piece meal
primarily hospital-focused approach being delivered in most
countries. Indeed, one example from Zambia illustrates what is
possible, and the attendant impact in a LMIC setting (11).
Implementation of hospital AMS programs in LMIC is
challenging (12), and even more so in the primary care or
community setting. For example, in 2014, despite over three
quarters of the member countries of the WHO Regional Office
of Africa (AFRO) having a medicine policy emphasizing rational
use of antibiotics, the majority of countries have limited capacity
to effectively implement these policies, particularly in primary
health care. The poor implementation of antibiotic policies
in most LMIC is attributed to the lack of enforcement of
the available polices and systems as well as the unavailability
of surveillance data and laboratory capacity for monitoring
antibiotic resistance (13).
It is therefore imperative that AMS interventions across all
systems are effectively implemented, given that MDR is a one-
system and one-health worldwide issue that won’t be controlled
without global intervention (14–16). The need for these global
interventions has been well-illustrated by the “One Health”
concept that includes not only the prescribers and the patients
(14), whether in the hospital or in the community, but also
animals and the environment. Of note, the tools available to
reduce the burden of antibiotic resistance should not be restricted
to AMS, as vaccines (17), infection control programs, and
improved sanitation (18), have all demonstrated their benefits
to reduce the emergence of MDR bacteria, when adequately
implemented at a large scale.
THE SPECIFIC POINTS TO CONDISER FOR
AMS PROGRAMS IN LMIC
There are several reasons why proven AMS programs that were
proven effective in HIC may not perform as well in LMIC,
and consequently their implementation “as it is” would provide
disappointing outcomes (19, 20). The main differences that
must be taken into account for the design and implementation
of AMS programs in LMIC, starting from the experience
gained in HIC, are summarized in Table 1. Firstly, while most
HIC have documented overconsumption of antibiotics, with
limited exceptions [namely, the Netherlands, and Scandinavian
countries, in Europe (21)], this may not be the case for most
LMIC. Actually, there are robust data to suggest that worldwide,
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TABLE 1 | Differences to take into account for the design of antimicrobial stewardship programs in low- and middle-income countries, as compared to high-income
countries.
High-income countries Low- and middle- income countries
Use of antibiotics (24)
- quantity 25 defined daily doses (DDD) per 1,000 inhabitants
per day
10 (low- and lower-middle-income countries), to 20
(higher-middle-income countries) DDD per 1,000
inhabitants per day
- trends 2000–2015 Steady Increasing (+77%)
- quality Regular monitoring Limited or no surveillance
Basic laboratory services with access to data
on antimicrobial resistance in human
pathogens
Routinely available for individual patients, and
periodic surveillance in different settings (hospitals,
community)
Limited or no data
Procurement of antibiotics Only if prescribed by medical doctors, with rare
exceptions
Highly heterogeneous, but often available through
the prescription of various health care workers, and
even without prescription in many settings (street
vendors)
Human resources available for antimicrobial
stewardship actions
Heterogeneous, and insufficient in most countries,
but increasing
Close to zero in many countries often not
considered as a priority
Education and training for health care workers
on antimicrobial resistance and use
Usually more extensive, both in pre-service as well
as in-service
Less time dedicated in pre-service schools
suboptimal in post-graduate settings, due to lack of
prioritization, human restrained resources, and
background
more patients die because they don’t have access to appropriate
antibiotics for easy-to-treat infections (e.g., pneumonia), than
because of antimicrobial resistance (22). Hence, while AMS
programs in HIC could safely target decreased consumption
of antibiotics, through the reduction of inappropriate use of
antibiotic, such targets may be dangerous in LMIC, where
increased access to appropriate antibiotics when needed should
be one of the top priorities (23). Although this may sound
provocative, a dramatic increase in antibiotics consumption,
as recently demonstrated in many LMIC (24), may indeed be
good news, as it may translate in millions of lives saved, if
these antibiotics are appropriately used. However, this positive
impact is definitely not guaranteed, due to the sub-optimal
qualification of health care workers and the limited technical
platform to guide diagnoses in LMIC. Of note, global point
prevalence survey showed that around 35% of antimicrobials
are misused in hospitals from LMIC in Latin America, Africa,
and Asia.
Secondly, in HIC, AMS programs are designed and
monitored, through laboratory surveillance of antimicrobial
resistance in inpatients, and outpatients. Sadly, the current status
of the diagnostic microbiology laboratory in LMIC would very
rarely allow such support for AMS programs (25). Although
point-prevalence surveys have demonstrated MDR bacteria have
emerged in many LMIC (26–28), with striking heterogeneity, in
humans as well as in animals (29), such data remain scarce: Many
colleagues in LMIC work in an environment where they have
no, or limited information about the prevalence of resistance to
the antibiotics they use in common situations. Even in countries
where surveillance is in place, updated, communication to
prescribers is sub-optimal. In most cases, there are no official
channels to disseminate the information, and prescribers do
not usually check for updated AMR data. This lack of baseline
information jeopardizes the implementation of appropriate AMS
programs, and the monitoring of their impact over time (30).
Thirdly, the architecture of the health care systems, broadly
heterogeneous in LMIC, must be cautiously evaluated and
taken into account before AMS programs are initiated. Even
well-planned interventions may have no benefit if they are
implemented in structures where patients rarely go. The
contextualization of AMS programs in LMIC is of paramount
importance, as inappropriate programs may even be deleterious,
in many aspects: (i) restriction of antibiotic use may be effective
and safe in countries with broad access to diagnostic tests, and
the possibility to closely monitor patients, but is more risky in
LMIC where such possibilities often don’t exist; (ii) although
prescription of antibiotics is limited to trained physicians in
most HIC, this is not the case in many LMIC, consequently
training limited to physiciansmay have limited impact, if patients
have easy access to antibiotics through other providers, including
various health care workers with limited or no training on AMS,
or even street vendors. Actually, task shifting from medical
doctors to non-specialist pharmacists and nurses for antibiotic
prescription may be feasible, and effective, but this has to be
contextualized (31, 32).
Culture is defined as the knowledge that people use to
develop shared beliefs, practices and norms that distinguish
one group of people from another, e.g., the culture across
different specialties, organizations or countries can influence
and shape behaviors and intervention outcomes. In the context
of implementing AMS programs this has been identified as
a key barrier to effective stewardship. A recent study across
HIC and LMIC documented a culture of hierarchies that
dominated the effectiveness and reach of AMS programs. For
example, professional boundaries limited the involvement of
nursing and pharmacy staff with doctors remaining the key
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stakeholders. An understanding of this could provide solutions
such as AMS champions and local leadership that can be used
to overcome hierarchical and rigid national and organizational
cultures (33).
Education and training in AMR is without doubt a keystone
to optimize the use of diagnostic tools, and for improving the use
of antimicrobials. By no means restricted to LMICs, the issues
of inadequate education and training in these settings may be
bigger both in pre and in-service. The scarcity of definition of
objectives and minimum contents to be taught and the lack of
harmonization between different universities in the same country
generate important gaps in knowledge. Regarding in-service,
there are less opportunities in LMICs for high-level training than
in HIC. By November 2019, WHO launched a curricula guide for
health worker’s education and training in AMR (34). This new
tool includes a systematic modular and submodular collection
of learning objectives and outcomes organized according to the
key occupational groups involved in the use of antimicrobials
in human health. The occupational groups covered include
prescribers of antimicrobials, nurses, midwives, pharmacists,
laboratory scientists, public health officers, and health services
managers. The goal of the curricula guide is to provide the
practical competencies to manage antimicrobials according to
their roles.
ANTIMICROBIAL STEWARDSHIP WITHIN
THE GLOBAL ACTION PLAN FOR
ANTIMICROBIAL RESISTANCE, AND
OTHER INTERNATIONAL INITIATIVES
In 2015, theWorld Health Organization (WHO) released a global
action plan on antimicrobial resistance (http://apps.who.int/
gb/ebwha/pdf_files/WHA68/A68_20-en.pdf), with five strategic
objectives: (i) to improve awareness and understanding of
antimicrobial resistance; (ii) to strengthen knowledge through
surveillance and research; (iii) to reduce the incidence of
infection; (iv) to optimize the use of antimicrobial agents; and
(v) to ensure sustainable investment in countering antimicrobial
resistance. The objective (iv) clearly encompasses to AMS, with
the following recommendation to member states: “Provision of
stewardship programs that monitor and promote optimization
of antimicrobial use at national and local levels in accordance
with international standards in order to ensure the correct choice
of medicine at the right dose on the basis of evidence”. The
WHO explicitly encourages “implementation of AMS programs
with international and national partners across multiple sectors,
accompanied by actions to ensure affordable and equitable
access by those who need them” (35). In line with this
call, two recommendations for implementing AMS programs
were launched. By November 2018, the Pan-American Health
Organization (PAHO/WHO), jointly with the Global Health
Consortium at the Florida International University (GHC/FIU)
published the “Recommendations for Implementing AMS
Programs in Latin America and the Caribbean,” including both
primary care settings and hospitals (36). In November 2019,
WHO published a practical toolkit for implementing AMS
programs in LMIC hospitals (37). The assets of local, regional,
and international collaboration with examples of good practices
or success stories were recently highlighted (38).
Five years after the launch of WHO global action plan, many
who have worked in the field have the feeling that, although
progress have been achieved (12, 39, 40), with remarkable success
stories (41–43), the actions undertaken to optimize the use of
antimicrobial agents do not match the challenges of emerging
antimicrobial resistance in most countries (23). In addition, the
durability of progress achieved in AMS requires sustained efforts,
otherwise the benefits may be rapidly lost (30, 43). In line with
the WHO global action plan, there are various initiatives led
by professional societies or non-governmental bodies, aimed
at reducing the emergence of antimicrobial resistance through
international collaborations over the last decades. Some are
described below:
- The Alliance for the Prudent Use of Antibiotics (APUA),
was founded in 1981 by Stuart Levy, one of the pioneers
in the fight against antimicrobial resistance, to “maximise
the effectiveness of antimicrobial treatment by promoting
appropriate antimicrobial use and containing drug resistance”.
With a broad international network of “chapters” in countries
from Africa, America, Asia, Europe and Oceania, APUA has
long been a major platform exchange, and facilitator of multi-
sectorial actions, from education to advocacy, targeting the
lay population as well as health care workers and politicians
(Figure 1). APUA merged with the AMS Working Group
of the International Society of Antimicrobial Chemotherapy
(ISAC) in 2019, to join forces for the promotion of better
use of antibiotics (https://apua.org/). A recent example of
APUA collaboration was the British Society for Antimicrobial
Chemotherapy (BSAC) highly impactful AMS collaboration
in the Middle East and Africa regions (https://apua.org/apua-
newsletter).
- ReAct, was initiated in 2005, with the goal to be a global
catalyst, advocating and stimulating for global engagement
on antimicrobial resistance by collaborating with a broad
range of organizations, individuals and stakeholders. It offers
open access to a broad range of information, and tools, to
support action against antimicrobial resistance worldwide.
ReAct was one of the first international independent networks
to articulate the complex nature of antimicrobial resistance
and its drivers (https://www.reactgroup.org/).
- The Global Antibiotic Resistance Partnership (GARP),
initiated in 2009, is a collaborative platform for
developing actionable policy proposals on antimicrobial
resistance (https://cddep.org/partners/global-antibiotic-
resistance-partnership/).
- In September 2016, the United Nations (UN)
issued the “declaration of the high-level meeting of
the General Assembly on antimicrobial resistance,”
(https://www.who.int/antimicrobial-resistance/events/UNGA
-meeting-amr-sept2016/en/), where nation leaders from
all over the world committed to fighting antimicrobial
resistance together. This was only the fourth time in the
history of the UN that a health topic was discussed at the
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FIGURE 1 | Alliance for the Prudent Use of Antibiotics (APUA) 2019 campaign.
General Assembly (HIV, non-communicable diseases, and
Ebola were the others), which illustrates the seriousness
and scope of the situation. Participating nations agreed
on sustainable, multi-sectoral approaches to addressing
antimicrobial resistance.
- Following the 2016 UN declaration, the Conscience of
Antimicrobial Resistance Accountability (CARA) initiative
was launched to monitor what is done to preserve the
effectiveness of antibiotics in every country on earth (https://
cddep.org/blog/posts/cara_conscience_antimicrobial_
resistance_accountability_and_next_big_thing_cddep/).
CARA was intended as “the eyes and ears of the world to track
what is actually being done, in service to the global leadership
that will lead the way following the UN General Assembly”.
TO START WITH SUCCESS: THE LOW
HANGING FRUITS
In front of the daunting task to fight the worldwide emergence
of antimicrobial resistance, it seems reasonable to target the
“low hanging fruits,” i.e., the actions that may be undertaken
with limited resources, in terms of funding and/or staff. These
principles have been applied with success in HIC as well, where
AMS has long remained neglected (and still is, in many aspects).
Hence, pioneer actions had to get started with no or limited
dedicated funding. For example, to reduce the duration of
antibacterial treatment for common infections has proven to
be quite easy to implement through training of prescribers,
with dissemination of guidelines, supported by randomized trials
that demonstrated the equivalent efficacy of short regimens
for community-acquired pneumonia, pyelonephritis, intra-
abdominal infections and other conditions. This has been one
of the most popular “low hanging fruits” for AMS teams in
the hospitals, and even in the community. It has been shown
that one can decrease by at least 30% the volume of antibiotic
prescription for common infections just by convincing hospital
colleagues to adjust the duration of treatment to what is needed,
with no additional risk of failure (44). On the other hands,
efforts to reduce the empirical use of antibiotics in patients with
suspicion of sepsis, or in patients with fever in the hematology
wards, is more complicated and would require much more
investment before the fruits will be picked, due to the limited
evidence behind the decision to prescribe, or not to prescribe,
antibiotics in those patients. Indeed, failure to initiate antibiotics
in those patients in case of need may have severe consequences,
while patients who really require antibiotics may be difficult
to identify.
Among the low hanging fruits identified for AMS actions
within LMIC, dissemination of educational material through
internet may be one of the most efficient and cost-effective. This,
of course, requires careful consideration of the objectives, and the
targets, as the messages must be adapted to the context. Several
initiatives have shown that clever use of modern communication
tools may indeed disseminate educational material, about the
importance of careful use of antimicrobial agents:
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- The e-bug initiative, launched in 2006 by Public Health
England, with initial co-funding by the European Commission
Directorate General for Health and Consumers, currently
involves a consortium of 28 partner’s countries. The main aim
of the project is to educate school children across the globe,
about microbiology, hygiene and the spread, treatment and
prevention of infectious diseases. e-Bug also aims to reinforce
an awareness of the benefits of prudent antibiotic use and how
inappropriate use can have an adverse effect on antimicrobial
resistance in the community (45). e-Bug provides free online
educational material with separate packs for teachers, and
students, including interactive lesson plans, complementary
games, and quizzes (https://e-bug.eu/).
- The Multidisciplinary French course on Antimicrobial
Stewardship in Africa (MUFASA) project was initiated in
2016 by Nazi Boni Universty (Burkina Faso), and Montpellier
University (France). The objectives are to raise awareness and
provide basic skills on AMS to 50–55 health care workers from
15 to 20 sub-Saharan African countries during 5 consecutive
weeks each year, with a consortium of international partners,
including WHO, the West African Health Organization
(WAHO), Fondation Mérieux, and the Société de Pathologie
Infectieuse de Langue Française (French Society of Infectious
Diseases, SPILF): http://www.diu-antibio.org. This has been
complimented in 2019 by a Massive Open Online course
(MOOC) specifically for the African context developed by
BSAC in collaboration with the Infection Control Africa
Network (ICAN), https://www.futurelearn.com/courses/
antimicrobial-stewardship-for-africa.
- The British Society for Antimicrobial Chemotherapy (BSAC),
a learned professional and charitable society, has taken
an impressive global and leadership role in developing,
disseminating and evaluating a range of AMR, and particularly
AMS, traditional and e-learning educational resources that
are high-quality, global in the their focus, and at all times
open access. For example, since 2015, BSAC has published 12
open access resources (http://bsac-vle.com), with a further
6 in development that have been used by 105,000+ learners
from 37,000+ locations across 182 countries, with translations
into five languages, with others planned (42). To-date, the
cost (less the in-kind staffing contribution from BSAC), of
development, roll-out, and ongoing support, is equivalent
to < $4 per learner. This is supplemented by the unique
open access AMS e-book developed by 39 authors across the
globe (http://bsac.org.uk/antimicrobial-stewardship-from-
principles-to-practice-e-book/), and the publication of JAC-
Antimicrobial Resistance (https://academic.oup.com/jacamr),
an innovative education and research platform that, for the
first time, offers academia and industry the opportunity
to submit their educational resources for peer review and
publication, allowing healthcare workers a global access to
peer-reviewed quality assured educational resource through
this and an associated database of WHO indexed non-peer
review free resources from across the globe (http://bsac-
jac-amr.com/jac-amr-resources/). A library of additional e-
resources is also available on the new infection management
learning hub—http://www.infectionlearninghub.co.uk.
CONCLUSIONS
The characteristics of antimicrobial use in LMIC are
heterogeneous, and must be taken into account when designing
any intervention that aims to maximize the effectiveness of
antimicrobial treatment, by promoting appropriate antimicrobial
use and containing drug resistance. The advent of antibiotics
almost one century ago has dramatically improved the prognosis
of most severe bacterial infections, which can still save millions
of lives, provided (i) severe bacterial infections are diagnosed,
and managed, in a timely manner; (ii) patients in need
have access to effective antibiotics; (iii) inappropriate use of
antibiotics is reduced, so that the emergence of antimicrobial
resistance does not jeopardize the success of antibiotics
currently available.
Despite the need to tailor AMS programs in the LMIC,
international collaborations remain highly valuable, through
the dissemination of high-quality documents, clinical
research and educational resources, that may be shared
worldwide. This process, which is relatively easy with modern
digital communication tools, combines many advantages,
including: (i) saving time, a precious dimension for health
care workers, by avoiding the duplication of similar works
in different settings worldwide; (ii) utilizing colleagues
skills and initiatives, through open access to their work
performed in other parts of the world; (iii) sharing experiences,
so that we all improve and learn from others successes
and failures.
AUTHOR CONTRIBUTIONS
PT wrote the first draft of the manuscript. DN, RL, GL,
AT, ME, GC, AV, HW, AP, ZD, and IG reviewed the first
draft and the final manuscript and provided critical comments.
All authors contributed to the article and approved the
submitted version.
REFERENCES
1. Alvarez FN, El-Sayed AM. National income inequality and ineffective health
insurance in 35 low- and middle-income countries.Health Policy Plan. (2017)
32:487–92. doi: 10.1093/heapol/czw156
2. IslamMS, Mondal MNI, Tareque MI, RahmanMA, Hoque MN, AhmedMM,
et al. Correlates of healthy life expectancy in low- and lower-middle-income
countries. BMC Public Health. (2018) 18:476. doi: 10.1186/s12889-018-5377-x
3. Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M.
Achieving global targets for antimicrobial resistance. Science. (2016)
353:874–5. doi: 10.1126/science.aaf9286
4. McGowan JE Jr, Gerding DN. Does antibiotic restriction prevent resistance?
New Horiz. (1996) 4:370–6.
5. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA,
Burke JP, et al. Infectious diseases society of america and the society for
healthcare epidemiology of america guidelines for developing an institutional
Frontiers in Medicine | www.frontiersin.org 6 August 2020 | Volume 7 | Article 503
Tattevin et al. Antimicrobial Stewardship in LMIC
program to enhance antimicrobial stewardship.Clin Infect Dis. (2007) 44:159–
77. doi: 10.1086/510393
6. Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship
programs from the centers for disease control and prevention. Clin Infect Dis.
(2014) 59(Suppl. 3):S97–100. doi: 10.1093/cid/ciu542
7. Pulcini C, Binda F, Lamkang AS, Trett A, Charani E, Goff DA, et al.
Developing core elements and checklist items for global hospital antimicrobial
stewardship programs: a consensus approach. Clin Microbiol Infect. (2019)
25:20–5. doi: 10.1016/j.cmi.2018.03.033
8. Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott MG, Darwish Elhajji
FW, et al. The impact of antibiotic use on the incidence and resistance
pattern of extended-spectrum beta-lactamase-producing bacteria in primary
and secondary healthcare settings. Br J Clin Pharmacol. (2012) 74:171–
9. doi: 10.1111/j.1365-2125.2011.04161.x
9. Ashiru-Oredope D, Budd EL, Bhattacharya A, Din N, McNulty CA,
Micallef C, et al. Implementation of antimicrobial stewardship interventions
recommended by national toolkits in primary and secondary healthcare
sectors in England: TARGET and start smart then focus. PLoS Med. (2016)
71:1408–14. doi: 10.1093/jac/dkv492
10. McLeod M, Ahmad R. A whole-health-economy approach to antimicrobial
stewardship: analysis of current models and future direction. PLoS Med.
(2019) 16:e1002774. doi: 10.1371/journal.pmed.1002774
11. Long A, Lungu JC, Machila E, Schwaninger S, Spector J, Tadmor B,
et al. A program to increase appropriate usage of benzathine penicillin for
management of streptococcal pharyngitis and rheumatic heart disease in
Zambia. Cardiovasc J Africa. (2017) 28:242–7. doi: 10.5830/CVJA-2017-002
12. Gebretekle GB, Haile Mariam D, Abebe W, Amogne W, Tenna A,
Fenta TG, et al. Opportunities and barriers to implementing antibiotic
stewardship in low and middle-income countries: lessons from a mixed-
methods study in a tertiary care hospital in Ethiopia. PLoS One. (2018)
13:e0208447. doi: 10.1371/journal.pone.0208447
13. Gelbrand H, Delahoy M. Policies to Address Antibiotic Resistance in
Low- and Middle-Income Countries. Cent Dis Dyn Econ Policy. (2014).
Available online at: https://www.cddep.org/sites/default/files/abrinlmics_
cddep_gelband_and_delahoy_9--14.pdf (accessed August 13, 2020).
14. Belongia EA, Schwartz B. Strategies for promoting judicious use
of antibiotics by doctors and patients. BMJ. (1998) 317:668–
71. doi: 10.1136/bmj.317.7159.668
15. Levy Hara G, Kanj SS, Pagani L, Abbo L, Endimiani A, Wertheim HF, et al.
Ten key points for the appropriate use of antibiotics in hospitalised patients: a
consensus from the antimicrobial stewardship and resistance working groups
of the international society of chemotherapy. Int J Antimicrob Agents. (2016)
48:239–46. doi: 10.1016/j.ijantimicag.2016.06.015
16. Levy-Hara G, Amabile-Cuevas CF, Gould I, Hutchinson J, Abbo L, Saxynger
L, et al. “Ten Commandments” for the appropriate use of antibiotics by
the practicing physician in an outpatient setting. Front Microbiol. (2011)
2:230. doi: 10.3389/fmicb.2011.00230
17. Feikin DR, Flannery B, Hamel MJ, Stack M, Hansen PM. Chapter 10:
Vaccines for children in low- and middle-income countries. In: Black
RE, Laxminarayan R, Temmerman M, Walker N, editors. Reproductive,
Maternal, Newborn, and Child Health: Disease Control Priorities, 3rd
ed, Vol. 2. Washington, DC: The International Bank for Reconstruction
and Development/The World Bank (c) 2016 International Bank for
Reconstruction and Development/The World Bank (2016). Available online
at: https://www.ncbi.nlm.nih.gov/books/NBK361927(accessed August, 13,
2020).
18. Loftus MJ, Guitart C, Tartari E, Stewardson AJ, Amer F, Bellissimo-Rodrigues
F, et al. Hand hygiene in low- and middle-income countries. Int J Infect Dis.
(2019) 86:25–30. doi: 10.1016/j.ijid.2019.06.002
19. Cox JA, Vlieghe E, Mendelson M, Wertheim H, Ndegwa L, Villegas
MV, et al. Antibiotic stewardship in low- and middle-income
countries: the same but different? Clin Microbiol Infect. (2017)
23:812–8. doi: 10.1016/j.cmi.2017.07.010
20. Haycox A. Should low- and middle-income countries adopt clinical
guidelines developed in ’rich’ countries? Pharmacoeconomics. (2018) 36:731–
2. doi: 10.1007/s40273-018-0666-x
21. McDonnell L, Armstrong D, Ashworth M, Dregan A, Malik U, White P.
National disparities in the relationship between antimicrobial resistance and
antimicrobial consumption in Europe: an observational study in 29 countries.
J Antimicrob Chemother. (2017) 72:3199–204. doi: 10.1093/jac/dkx248
22. Laxminarayan R, Matsoso P, Pant S, Brower C, Rottingen JA, Klugman K,
et al. Access to effective antimicrobials: a worldwide challenge. Lancet. (2016)
387:168–75. doi: 10.1016/S0140-6736(15)00474-2
23. Mendelson M, Rottingen JA, Gopinathan U, Hamer DH, Wertheim
H, Basnyat B, et al. Maximising access to achieve appropriate human
antimicrobial use in low-income andmiddle-income countries. Lancet. (2016)
387:188–98. doi: 10.1016/S0140-6736(15)00547-4
24. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA,
et al. Global increase and geographic convergence in antibiotic consumption
between 2000 and 2015. Proc Natl Acad Sci USA. (2018) 115:E3463–
70. doi: 10.1073/pnas.1717295115
25. Nkengasong JN, Yao K, Onyebujoh P. Laboratory medicine in low-income
and middle-income countries: progress and challenges. Proc Natl Acad Sci
USA. (2018) 391:1873–5. doi: 10.1016/S0140-6736(18)30308-8
26. Ouedraogo AS, Dunyach-Remy C, Kissou A, Sanou S, Poda A,
Kyelem CG, et al. High nasal carriage rate of staphylococcus aureus
containing panton-valentine leukocidin- and EDIN-encoding genes in
community and hospital settings in Burkina Faso. Front Microbiol. (2016)
7:1406. doi: 10.3389/fmicb.2016.01406
27. Ouedraogo AS, Sanou S, Kissou A, Poda A, Aberkane S, Bouzinbi
N, et al. Fecal carriage of enterobacteriaceae producing extended-
spectrum beta-lactamases in hospitalized patients and healthy
community volunteers in Burkina Faso. Microb Drug Resist. (2017)
23:63–70. doi: 10.1089/mdr.2015.0356
28. Singh N, Manchanda V. Control of multidrug-resistant Gram-
negative bacteria in low- and middle-income countries-high impact
interventions without much resources. Clin Microbiol Infect. (2017)
23:216–8. doi: 10.1016/j.cmi.2017.02.034
29. Schar D, Sommanustweechai A, Laxminarayan R, Tangcharoensathien
V. Surveillance of antimicrobial consumption in animal production
sectors of low- and middle-income countries: optimizing use
and addressing antimicrobial resistance. PLoS Med. (2018)
15:e1002521. doi: 10.1371/journal.pmed.1002521
30. Dondorp AM, Limmathurotsakul D, Ashley EA. What’s wrong in
the control of antimicrobial resistance in critically ill patients from
low- and middle-income countries? Intensive Care Med. (2018)
44:79–82. doi: 10.1007/s00134-017-4795-z
31. Bulabula ANH, Jenkins A, Mehtar S, Nathwani D. Education and
management of antimicrobials amongst nurses in Africa-a situation analysis:
an infection control Africa Network (ICAN)/BSAC online survey. J
Antimicrob Chemother. (2018) 73:1408–15. doi: 10.1093/jac/dky023
32. Brink A, Van den Bergh D, Mendelson M, Richards GA. Passing the baton
to pharmacists and nurses: new models of antibiotic stewardship for South
Africa? S Afr Med J. (2016) 106:947–8. doi: 10.7196/SAMJ.2016.v106i10.
11448
33. Charani E, Smith I, Skodvin B, Perozziello A, Lucet JC, Lescure
FX, et al. Investigating the cultural and contextual determinants
of antimicrobial stewardship programs across low-, middle- and
high-income countries-A qualitative study. PLoS ONE. (2019)
14:e0209847. doi: 10.1371/journal.pone.0209847
34. Health Workers’ Education and Training on Antimicrobial Resistance:
Curricula Guide. Geneva: World Health Organization (2019). Available
online at: https://www.who.int/news-room/detail/17--10-2019-global-
symposium-on-health-workforce-accreditation-and-regulation-december-
2019 (accessed August 13, 2020).
35. WHO Member States Adopt Global Action Plan on Antimicrobial Resistance.
Euro Surveill (2015). p. 20.
36. Pan American Health Organization. Florida International University.
Recommendations for Implementing Antimicrobial Stewardship Programs in
Latin America and the Caribbean: Manual for Public Health Decision-Makers.
(2018). Available online at: http://iris.paho.org/xmlui/handle/123456789/
49645 (accessed August 13, 2020).
37. World Health Organization. Antimicrobial Stewardship Programs in Health-
Care Facilities in Low- and Middle-Income Countries. A Practical Toolkit.
(2019). Available online at: https://apps.who.int/iris/handle/10665/329404
(accessed August 13, 2020).
Frontiers in Medicine | www.frontiersin.org 7 August 2020 | Volume 7 | Article 503
Tattevin et al. Antimicrobial Stewardship in LMIC
38. Goff DA, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, Cairns KA,
et al. A global call from five countries to collaborate in antibiotic stewardship:
united we succeed, divided we might fail. Lancet Infect Dis. (2017) 17:e56–
63. doi: 10.1016/S1473-3099(16)30386-3
39. Sonda TB, Horumpende PG, Kumburu HH, van Zwetselaar M, Mshana SE,
Alifrangis M, et al. Ceftriaxone use in a tertiary care hospital in Kilimanjaro,
Tanzania: A need for a hospital antibiotic stewardship programme. PLoS One.
(2019) 14:e0220261. doi: 10.1371/journal.pone.0220261
40. Van Dijck C, Vlieghe E, Cox JA. Antibiotic stewardship interventions in
hospitals in low-and middle-income countries: a systematic review. Bull
World Health Organ. (2018) 96:266–80. doi: 10.2471/BLT.17.203448
41. Rupali P, Palanikumar P, Shanthamurthy D, Peter JV, Kandasamy S, Zacchaeus
NGP, et al. Impact of an antimicrobial stewardship intervention in India:
evaluation of post-prescription review and feedback as amethod of promoting
optimal antimicrobial use in the intensive care units of a tertiary-care hospital.
Infect Control Hosp Epidemiol. (2019) 40:512–9. doi: 10.1017/ice.2019.29
42. Sneddon J, Barlow G, Bradley S, Brink A, Chandy SJ, Nathwani D.
Development and impact of a massive open online course (MOOC)
for antimicrobial stewardship. J Antimicrob Chemother. (2018) 73:1091–
7. doi: 10.1093/jac/dkx493
43. Hamilton D, Bugg I. Improving antimicrobial stewardship in the outpatient
department of a district general hospital in Sierra Leone. BMJ Open Qual.
(2018) 7:e000495. doi: 10.1136/bmjoq-2018-000495
44. Avdic E, Cushinotto LA, Hughes AH, Hansen AR, Efird LE, Bartlett
JG, et al. Impact of an antimicrobial stewardship intervention
on shortening the duration of therapy for community-acquired
pneumonia. Clin Infect Dis. (2012) 54:1581–7. doi: 10.1093/cid/
cis242
45. McNulty CA, Lecky DM, Farrell D, Kostkova P, Adriaenssens
N, Koprivova Herotova T, et al. Overview of e-Bug: an
antibiotic and hygiene educational resource for schools. J
Antimicrob Chemother. (2011) 66(Suppl. 5):v3–12. doi: 10.1093/jac/
dkr119
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Tattevin, Levy Hara, Toumi, Enani, Coombs, Voss, Wertheim,
Poda, Daoud, Laxminarayan, Nathwani and Gould. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Medicine | www.frontiersin.org 8 August 2020 | Volume 7 | Article 503
